Best practice for ERT?

Before leaving that day, Ashley asked, “Did you check out the Internet? Did you read about the horses?” I did know about the horses, and I understood why she, the animal loving vegetarian, had insisted on nonequine estrogen. Anyone wishing to know about the fate of the horses and their foals should search pregnant mare’s urine on the Internet.There is ample precedent for a movement away from animal sources for hormone replacement. Recombinant human technology has been used to make thyroxine and insulin rather than relying on older hormones extracted from beef and pork. After reviewing the scientific and ethical issues, we decided that in most cases, it was best practice to prescribe estrogens identical to that found in the human body rather than those derived from animals.  

Our experience with Ashley changed our prescribing practice. Today we wonder why anyone, in pediatric or adult practice, would prescribe animal-derived hormones when those identical to that produced by the human female body are available?19

Eileen Durham, C-PNP, CNS, MSN, is a pediatric nurse practitioner in the Division of Pediatric Endocrinology & Diabetes at Lucile Packard Children’s Hospital at Stanford in Palo Alto, California.


Continue Reading

References

1. Kiess W, Conway G, Ritzen M, et al. Induction of puberty in the hypogonadal girl—practices and attitudes of pediatric endocrinologists in Europe. Horm Res. 2002;57:66-71.

2. Sanders TA, Reddy S. Vegetarian diets and children. Am J Clin Nutr. 1994;59:1176S -1181S.

3. Kenyon PM, Barker ME. Attitudes towards meat-eating in vegetarian and non-vegetarian teenage girls in England — an ethonographic approach. Appetite. 1998;30:185-198.

4. Fox N, Ward K. Health, ethics and environment: a qualitative study of vegetarian motivations. Appetite. 2008;50:422-429.

5. Di Genova T, Guyda H. Infants and children consuming atypical diets: vegetarianism and macrobiotics. Paediatr Child Health. 2007;12:185-188.

6. Rosenfield RL, Cooke DW, Radovick S. “Puberty and its disorders in the female.” In: Sperling, MA, ed. Pediatric Endocrinology. 3rd ed. Philadelphia, Pa.: Saunders Elsevier; 2008:530-609.

7. Holtorf K. “The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?” Postgrad Med. 2009;121:73-85.

8. Lantinga GM, Simons AH, Kamps WA, Postma A. Imminent ovarian failure in childhood cancer survivors. Eur J Cancer. 2006;42:1415-1420.

9. Hershlag A, Rausch ME, Cohen M. Part 2: Ovarian failure in adolescent cancer survivors should be treated. J Pediatr Adolesc Gynecol. 2011;24:101-103.

10. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005;118 Suppl 12B:64-73.

11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. 

12. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712. 

13.Taboada M, Santen R, Lima J, et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome. J Clin Endocrinol Metab. 2011;96:3502-3510.

14. The Endocrine Society. Position statement: bioidentical hormones. October 2006.

15. Dong B. Hormonal drugs: Female sex hormones. In: Anderson PO, Knoben JE, Troutman WG, eds. Handbook of Clinical Drug Data. 10th ed. New York, N.Y.: McGraw-Hill; 2002:679-698.

16. Janssen YJ, Helmerhorst F, Frölich M, Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-1 levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab. 2000;85:464-467. 

17. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Atheroscler Thromb Vasc Biol. 1997;17:3071-3078.

18. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317- 2322.

19. Bondy CA, Ceniceros I, Lange E, Bakalov VK. Declining estrogen use in young women with Turner syndrome. Arch Intern Med. 2006;166:1322-1345.

All electronic documents accessed December 15, 2011.